CAI Yutian,GUO Yuan,GUO Ningning,et al.Application of Endocan in the Diagnosis of Dermatological Diseases[J].The Chinese Journal of Dermatovenereology,2019,(07):836-839.[doi:10.13735/j.cjdv.1001-7089.201804016]





Application of Endocan in the Diagnosis of Dermatological Diseases
1.江苏大学医学院,江苏 镇江 212001; 2.江苏大学附属医院皮肤科,江苏 镇江 212001
CAI Yutian12GUO Yuan12GUO Ningning12LIU Liping12LI Yumei12
(1.Medical College of Jiangsu University,Zhenjiang 212001,China; 2.Department of Dermatology,Affiliated Hospital of Jiangsu University,Zhenjiang 212001,China)
Endocan/ESM-1 内皮细胞特异性分子-1 新型标志物 皮肤病
Endocan/ESM-1 Endothelial cell specific molecule-1 New marker Skin diseases
R 751
Endocan又称内皮细胞特异性分子-1(endothelial cell specific molecule-1,ESM-1),是一种可溶性硫酸皮肤素蛋白聚糖(DSPG),在正常人体内主要由肺、肾脏血管内皮细胞分泌,受细胞因子、血管生长因子、转录因子等多种因素的复杂调控。初步研究表明,Endocan与血管、淋巴管的生成及多种生物分子调控机制有关,其在炎症和肿瘤的发生发展中起重要作用。近年研究发现,Endocan也参与了多种皮肤病的病理过程,其或可对皮肤病的诊断和预后评估具有临床意义。
Endocan,also known as endothelial cell specific molecule-1(ESM-1),is a soluble dermatan sulfate proteoglycan(DSPG)that is secreted by the vascular endothelial cells of the lung and kidney.Endocan is regulated by a number of factors such as cytokines,VEGF and TNF.Preliminary studies show that Endocan is associated with angiogenesis,lymphangiogenesis and regulatory mechanisms of many biomolecules,which plays important roles in the development and progression of inflammation and cancer.Recently,studies have found that Endocan is involved in the pathological progress of various skin diseases,which may have clinical application for diagnosis and prognostic assessment in dermatological diseases.


[1] Lassalle P,Molet S,Janin A,et al.ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines[J].J Biol Chem,1996,271(34):20458-20464.
[2] Sarrazin S,Lyon M,Deakin JA,et al.Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan,a soluble endothelial proteoglycan[J].Glycobiology,2010,20(11):1380-1388.
[3] Pauly D,Hamed S,Behnes M,et al.Endothelial cell-specific molecule-1/Endocan:Diagnostic and prognostic value in patients suffering from severe sepsis and septic shock[J].J Crit Care,2016,31(1):68-75.
[4] Dieterich LC,Mellberg S,Langenkamp E,et al.Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization[J].J Pathol,2015,228(3):378-390.
[5] Rennel E,Mellberg S,Dimberg A,et al.Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer[J].Exp Cell Res,2007,313(7):1285-1294.
[6] Zhu Y,Zhang X,Qi L,et al.HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas[J].Oncotarget,2016,7(12):14429-14440.
[7] Béchard D,Scherpereel A,Hammad H,et al.Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18(LFA-1)and blocks binding to intercellular adhesion molecule-1[J].J Immunol,2001,167(6):3099-3106.
[8] Hsiao SY,Kung CT,Tsai NW,et al.Concentration and value of endocan on outcome in adult patients after severe sepsis[J].Clin Chim Acta,2018,483:275-280.
[9] Ioakeimidou A,Pagalou E,Kontogiorgi M,et al.Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction[J].Eur J Clin Microbiol Infect Dis,2017,36(10):1749-1756.
[10] Mihajlovic DM,Lendak DF,Brkic SV,et al.Endocan is useful biomarker of survival and severity in sepsis[J].Microvasc Res,2014,93(5):92-97.
[11] Scherpereel A,Gentina T,Grigoriu B,et al.Overexpression of endocan induces tumor formation[J].Cancer Res,2003,63(18):6084-6089.
[12] Roudnicky F,Poyet C,Wild P,et al.Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis[J].Cancer Res,2013,189(4):e459-e459.
[13] Arslan B,Onuk Ö,Hazar Ï,et al.Prognostic value of endocan in prostate cancer:clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy[J].Tumori,2017,103(2):204-208.
[14] Bai F,Zheng W,Dong Y,et al.Serum levels of adipokines and cytokines in psoriasis patients:a systematic review and meta-analysis[J].Oncotarget,2018,9(1):1266-1278.
[15] Balta I,Balta S,Demirkol S,et al.Elevated serum levels of endocan in patients with psoriasis vulgaris:correlations with cardiovascular risk and activity of disease[J].Br J Dermatol,2013,169(5):1066-1070.
[16] 马小娜,王爽,张辉,等.寻常性银屑病患者光疗后血清内皮细胞特异性分子及nesfatin-1水平变化[J].临床皮肤科杂志,2017,46(4):243-246.
[17] Erek Toprak A,Ozlu E,Uzuncakmak TK,et al.Neutrophil/lymphocyte ratio,serum endocan,and nesfatin-1 levels in patients with psoriasis vulgaris undergoing phototherapy treatment[J].Med Sci Monit,2016,22:1232-1237.
[18] Owczarczyksaczonek A,Drozdowski M,Maciejewskaradomska A,et al.The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients-preliminary report[J].Postepy Dermatol Alergol,2018,35(1):53-59.
[19] Suzuki H,Miyagaki T,Otobe S,et al.Increased endocan expression in lesional skin and decreased endocan expression in sera in atopic dermatitis[J].J Dermatol,2017,44(12):1392.
[20] 瞿旻晔,袁晓琳,马健.特应性皮炎发病过程及其机制研究现状探讨[J].中国皮肤性病学杂志,2015,29(10):1085-1087.
[21] Hammad MA,Abdel-Latif SM,Shehata OZ,et al.Clinical significance of endocan in Behçet's disease patients:A potential marker of disease activity[J].Eg Rheum,2018,41(1):59-64.
[22] Blnescu P,Ldaru A,Blnescu E,et al.Endocan,novel potential biomarker for systemic sclerosis:results of a pilot study[J].J Clin Lab Anal,2016,30(5):368-373.
[23] Chen Y,Leask A,Abraham DJ,et al.Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts[J].Arthritis Rheum,2008,58(2):577-585.
[24] Syed D,Iqbal O,Mosier M,et al.Elevated endocan levels and its association with clinical severity in stevens johnson syndrome and toxic epidermal necrolysis[J].Int Angiol,2015,34(5):483-488.


[基金项目] 2015年国家自然科学基金面上项目(81573053); 2015江苏省“333工程”培养资金资助项目(BRA2015196); 镇江市第七批科技计划(SS2015024)
[作者单位] 1.江苏大学医学院,江苏 镇江 212001; 2.江苏大学附属医院皮肤科,江苏 镇江 212001
[通讯作者] 李遇梅,E-mail:l.yumeili@ujs.edu.cn
[Corresponding author] LI Yumei,E-mail:l.yumeil
更新日期/Last Update: 2019-06-15